• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用血小板生成素激动剂艾曲泊帕使狼疮相关血小板减少症患者的血小板计数成功恢复。

Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.

作者信息

Scheinberg Phillip, Singulane Cristiane Carvalho, Barbosa Luis Sergio Guedes, Scheinberg Morton

机构信息

Hematology Service, Oncology Center, Hospital São José, Beneficência Portuguesa, São Paulo, Brazil.

出版信息

Clin Rheumatol. 2014 Sep;33(9):1347-9. doi: 10.1007/s10067-014-2600-8. Epub 2014 Apr 17.

DOI:10.1007/s10067-014-2600-8
PMID:24740463
Abstract

Eltrombopag is a new thrombomimetic medication approved for the treatment of immune thrombocytopenia. There are very few reports on the use of eltrombopag in patients with thrombocytopenia associated with sytemic lupus.We present a recent case of a patient with lupus with severe thrombocytopenia refractory to conventional therapy and full recovery with the use of eltrombopag. The present status of the literature with the use of this medication in patients with lupus is reviewed and discussed.

摘要

艾曲泊帕是一种新的拟血栓形成药物，已被批准用于治疗免疫性血小板减少症。关于艾曲泊帕在系统性红斑狼疮相关血小板减少症患者中的应用报道极少。我们报告了一例近期的狼疮患者病例，该患者严重血小板减少，对传统治疗无效，但使用艾曲泊帕后完全康复。本文对该药物在狼疮患者中的应用现状进行了综述和讨论。

相似文献

1
Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.使用血小板生成素激动剂艾曲泊帕使狼疮相关血小板减少症患者的血小板计数成功恢复。
Clin Rheumatol. 2014 Sep;33(9):1347-9. doi: 10.1007/s10067-014-2600-8. Epub 2014 Apr 17.
2
Treatment of severe thrombocytopenia associated with systemic lupus erythematosus in pregnancy with eltrombopag: A case report and literature review.妊娠期系统性红斑狼疮相关严重血小板减少症采用艾曲波帕治疗：病例报告及文献复习。
J Clin Pharm Ther. 2021 Apr;46(2):532-538. doi: 10.1111/jcpt.13321. Epub 2020 Dec 5.
3
Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.使用血小板生成素受体激动剂艾曲泊帕成功治疗慢性粒单核细胞白血病患者的严重血小板减少症。
J Oncol Pharm Pract. 2015 Feb;21(1):74-5. doi: 10.1177/1078155214544076. Epub 2014 Jul 24.
4
Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).艾曲泊帕成功治疗一名系统性红斑狼疮（SLE）患者的无巨核细胞性血小板减少症。
Clin Adv Hematol Oncol. 2010 Nov;8(11):806-9.
5
Eltrombopag in thrombocytopenia.艾曲泊帕治疗血小板减少症。
N Engl J Med. 2008 Mar 6;358(10):1072; author reply 1072-3. doi: 10.1056/NEJMc073571.
6
Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.血小板生成素受体激动剂治疗系统性红斑狼疮相关难治性免疫性血小板减少症的疗效
J Rheumatol. 2014 Sep;41(9):1895-6. doi: 10.3899/jrheum.140080.
7
Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.口服非肽类血小板生成素受体激动剂艾曲泊帕的1期临床研究。
Blood. 2007 Jun 1;109(11):4739-41. doi: 10.1182/blood-2006-11-057968. Epub 2007 Feb 27.
8
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.艾曲泊帕与安慰剂治疗血小板减少的低危骨髓增生异常综合征（EQoL-MDS）：一项单盲、随机、对照、2期优效性试验的1期结果
Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3.
9
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.艾曲泊帕用于丙型肝炎相关肝硬化患者的血小板减少症
N Engl J Med. 2007 Nov 29;357(22):2227-36. doi: 10.1056/NEJMoa073255.
10
Molecule of the month. Eltrombopag.本月分子。艾曲泊帕。
Drug News Perspect. 2008 Jul-Aug;21(6):344.

引用本文的文献

1
Eltrombopag in severe immune thrombocytopenia secondary to connective tissue disease: a report of 17 patients and literature review.艾曲泊帕治疗结缔组织病继发的严重免疫性血小板减少症：17例病例报告及文献综述
Clin Rheumatol. 2023 May;42(5):1451-1457. doi: 10.1007/s10067-022-06464-w. Epub 2023 Jan 3.
2
Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan.在日本，免疫抑制治疗初治的再生障碍性贫血患者中，联合用艾曲波帕与兔抗胸腺细胞球蛋白/环孢素 A。
Intern Med. 2021 Apr 15;60(8):1159-1168. doi: 10.2169/internalmedicine.6063-20. Epub 2020 Nov 23.
3

本文引用的文献

1
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.依鲁替尼可恢复对药物停药后可维持缓解的难治性重型再生障碍性贫血的三系造血。
Blood. 2014 Mar 20;123(12):1818-25. doi: 10.1182/blood-2013-10-534743. Epub 2013 Dec 17.
2
Hematological disorders in patients with systemic lupus erythematosus.系统性红斑狼疮患者的血液系统疾病
Open Rheumatol J. 2013 Oct 18;7:87-95. doi: 10.2174/1874312901307010087. eCollection 2013.
3
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Lupus thrombocytopenia: pathogenesis and therapeutic implications.
狼疮性血小板减少症：发病机制及治疗意义
Mediterr J Rheumatol. 2017 Mar 28;28(1):20-26. doi: 10.31138/mjr.28.1.20. eCollection 2017 Mar.
4
Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.隐匿性阴谋家：关于血小板减少症和抗磷脂综合征的对话。
Curr Opin Rheumatol. 2019 May;31(3):231-240. doi: 10.1097/BOR.0000000000000595.
5
Eltrombopag Improves Refractory Thrombocytopenia in a Patient with Systemic Lupus Erythematosus.艾曲泊帕改善了一名系统性红斑狼疮患者的难治性血小板减少症。
Case Rep Rheumatol. 2018 Aug 15;2018:6305356. doi: 10.1155/2018/6305356. eCollection 2018.
托法替布联合非生物性疾病修正抗风湿药物治疗活动期类风湿关节炎患者的随机试验。
Ann Intern Med. 2013 Aug 20;159(4):253-61. doi: 10.7326/0003-4819-159-4-201308200-00006.
4
Immune thrombocytopenia -- what are the new treatment options?免疫性血小板减少症——有哪些新的治疗选择？
Expert Opin Biol Ther. 2013 Aug;13(8):1173-85. doi: 10.1517/14712598.2013.801451. Epub 2013 May 17.
5
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.慢性免疫性血小板减少症患者使用罗米司亭的长期治疗：安全性和疗效。
Br J Haematol. 2013 May;161(3):411-23. doi: 10.1111/bjh.12260. Epub 2013 Feb 22.
6
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.依曲泊帕治疗慢性免疫性血小板减少症的安全性和有效性：长期、开放性 EXTEND 研究结果。
Blood. 2013 Jan 17;121(3):537-45. doi: 10.1182/blood-2012-04-425512. Epub 2012 Nov 20.
7
Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus.妊娠系统性红斑狼疮患者应用罗米司亭成功治疗严重血小板减少症。
Lupus. 2012 Dec;21(14):1571-4. doi: 10.1177/0961203312463621.
8
Eltrombopag and improved hematopoiesis in refractory aplastic anemia.依鲁替尼改善再生障碍性贫血的造血功能。
N Engl J Med. 2012 Jul 5;367(1):11-9. doi: 10.1056/NEJMoa1200931.
9
Thrombopoietin-receptor agonists for primary immune thrombocytopenia.用于原发性免疫性血小板减少症的血小板生成素受体激动剂
N Engl J Med. 2011 Aug 25;365(8):734-41. doi: 10.1056/NEJMct1014202.
10
Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).艾曲泊帕成功治疗一名系统性红斑狼疮（SLE）患者的无巨核细胞性血小板减少症。
Clin Adv Hematol Oncol. 2010 Nov;8(11):806-9.